Bellerophon Announces Poster Presentation on INOpulse® at 37th Annual Meeting for the International Society for Heart and Lung Transplantation
March 27, 2017 08:00 ET | Bellerophon Therapeutics LLC
WARREN, N.J., March 27, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced a poster presentation at the 37th Annual...
Bellerophon Reports Fourth Quarter 2016 Financial Results and Provides Business Update
March 13, 2017 07:30 ET | Bellerophon Therapeutics LLC
WARREN, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial...
Bellerophon Therapeutics Announces FDA Acceptance of Modifications to INOpulse Pulmonary Arterial Hypertension Phase 3 Program
January 04, 2017 08:00 ET | Bellerophon Therapeutics LLC
WARREN, N.J., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it received confirmation from the...
Bellerophon Therapeutics, Inc. Announces $12 Million Public Offering
November 23, 2016 06:30 ET | Bellerophon Therapeutics LLC
WARREN, N.J., Nov. 23, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the pricing of a public offering with expected...
Bellerophon Reports Third Quarter 2016 Financial Results and Provides Business Update
November 08, 2016 07:03 ET | Bellerophon Therapeutics LLC
WARREN, N.J., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today reported financial results for the third quarter...
Bellerophon Therapeutics Announces Planned Management Transition by Year-End 2016
September 20, 2016 06:33 ET | Bellerophon Therapeutics LLC
WARREN, N.J., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the planned transition of Fabian Tenenbaum,...
Bellerophon to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
September 06, 2016 06:37 ET | Bellerophon Therapeutics LLC
WARREN, N.J., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it will present at the 18th Annual...
Bellerophon Reports Second Quarter 2016 Financial Results and Provides Business Update
August 09, 2016 06:33 ET | Bellerophon Therapeutics LLC
WARREN, N.J., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today reported financial results for the second quarter...
Bellerophon Receives Approval to Commence Phase 2 Trial in PH-COPD
July 25, 2016 06:03 ET | Bellerophon Therapeutics LLC
-- Trial expected to commence in third quarter; Results to be reported by year end 2016 ---- Previous data supporting testing long-term benefits of pulsed inhaled nitric oxide (iNO) reported in...
Bellerophon Therapeutics Announces Enrollment of the First Patient in the INOvation-1 Phase 3 Clinical Trial for Pulmonary Arterial Hypertension (PAH)
June 16, 2016 06:03 ET | Bellerophon Therapeutics LLC
WARREN, N.J., June 16, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, announced today that the first subject has been enrolled...